Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. VYNE Therapeutics Inc shares valued at $43,800 were purchased by LEPORE PATRICK G on Jan 15 ’25. At $2.92 per share, LEPORE PATRICK G acquired 15,000 shares. The insider’s holdings grew to 51,472 shares worth approximately $48383.68 following the completion of this transaction.
As published in their initiating research note from BTIG Research on November 18, 2024, VYNE Therapeutics Inc [VYNE] has been a Buy and the price target has been revised to $8.
Analyzing VYNE Stock Performance
On last trading session,, VYNE Therapeutics Inc [NASDAQ: VYNE] rose 2.37% to $0.94. The stock’s lowest price that day was $0.902, but it reached a high of $0.96 in the same session. During the last five days, there has been a surge of approximately 2.02%. Over the course of the year, VYNE Therapeutics Inc shares have dropped approximately -71.93%. Shares of the company reached a 52-week high of $4.3000 on 01/08/25 and a 52-week low of $0.8800 on 06/16/25.
Support And Resistance Levels for VYNE Therapeutics Inc (VYNE)
According to the 24-hour chart, there is a support level at 0.9083, which, if violated, would cause prices to drop to 0.8761. In the upper region, resistance lies at 0.9663. The next price resistance is at 0.9921. RSI (Relative Strength Index) is 34.97 on the 14-day chart, showing neutral technical sentiment.
Is VYNE Therapeutics Inc subject to short interest?
Stocks of VYNE Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.12 million shares to 0.33 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 0.22 million shares. A jump of 35.0% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.3 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.3.
Which companies own the most shares of VYNE Therapeutics Inc (VYNE)?
In terms of VYNE Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5.75 in the next 12 months, up nearly 525.0% from the previous closing price of $0.92. Analysts anticipate VYNE Therapeutics Inc stock to reach 5.75 by 2025, with the lowest price target being 5.75. In spite of this, 1 analysts ranked VYNE Therapeutics Inc stock as Buy at the end of 2025.
